Losartan Use in Chronic Intracerebral Hemorrhage – Evidence‑Based Recommendations

Indications and Safety Profile

The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines list losartan as a primary antihypertensive agent for long‑term blood‑pressure control in patients with chronic intracerebral hemorrhage (ICH), provided there is no bilateral renal artery stenosis, severe renal impairment, or hyper‑kalemia.  [1][2]3

Losartan should not be initiated in patients with severe bilateral renal‑artery stenosis because of the risk of acute renal failure. [1][2]3
A documented history of angioedema with any angiotensin‑receptor blocker constitutes an absolute contraindication to losartan therapy. [1][2]
Pregnancy is a contraindication; losartan must be avoided in pregnant individuals. [1][2]3
Concomitant use of losartan with an ACE inhibitor or a direct renin inhibitor is not recommended due to potential harm. 2

Losartan increases the risk of hyper‑kalemia, especially in patients with chronic kidney disease or those receiving potassium‑supplementing agents; clinicians should be vigilant for this adverse effect. [1][2]3

Initiate therapy with losartan 50 mg taken once daily; this dose is the most frequently used and well‑tolerated in chronic ICH safety studies. [1][2]3
If target systolic blood pressure (<130 mm Hg) is not achieved on 50 mg, increase the dose to 100 mg once daily. [1][2]3
When monotherapy with losartan is insufficient, adding hydrochlorothiazide is an acceptable strategy to achieve blood‑pressure goals. [1][2]

Re‑measure office blood pressure one month after starting losartan to assess response and guide further titration. [1][2]6

In acute ICH (within hours to days), the 2024 European Society of Cardiology (ESC) guidelines recommend rapid reduction of systolic blood pressure to <180 mm Hg for patients presenting with systolic ≥220 mm Hg. [7][8]
The 2014 European Stroke Organization (ESO) guidelines advise intensive blood‑pressure lowering to a systolic target <140 mm Hg within the first 6 hours of acute ICH onset. 9
For chronic ICH survivors, the acute‑phase restrictions do not apply; long‑term secondary‑prevention strategies prioritize sustained blood‑pressure control, and losartan is endorsed as a primary antihypertensive agent. [1][2]3